तुलना करने के लिए मीट्रिक्स | ESLA | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधESLAपीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −1.2x | −2.8x | −0.2x | |
PEG अनुपात | −0.07 | −0.05 | 0.00 | |
क़ीमत/बुक | −1.1x | 4.2x | 2.6x | |
क़ीमत / एलटीएम बिक्री | - | 9.0x | 2.7x | |
अपसाइड (विश्लेषक लक्ष्य) | - | 277.2% | 72.2% | |
उचित मूल्य अपसाइड | अनलॉक करें | −1.8% | 12.4% | अनलॉक करें |
Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company’s lead product candidate is EB103, which is in Phase I/II clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus. It offers ARTEMIS, a cell receptor platform to develop and commercialize T-cell therapies targeting CD19 and CD22 for the treatment of hematologic malignancies. It has a collaborative agreement with Eureka and Imugene Limited for the development of solid tumor treatments using Imugene’s product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. was founded in 2006 and is headquartered in EmeryVille, California. Estrella Immunopharma, Inc. is a subsidiary of Eureka Therapeutics, Inc.